BNP Paribas Has $5.57 Million Holdings in Pfizer Inc. (NYSE:PFE)

BNP Paribas boosted its holdings in Pfizer Inc. (NYSE:PFE) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,456 shares of the biopharmaceutical company’s stock after purchasing an additional 4,203 shares during the quarter. BNP Paribas’ holdings in Pfizer were worth $5,573,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Pfizer by 528.7% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,668,833 shares of the biopharmaceutical company’s stock worth $106,176,000 after purchasing an additional 3,085,233 shares during the period. Clifford Capital Partners LLC lifted its position in shares of Pfizer by 9.6% during the 3rd quarter. Clifford Capital Partners LLC now owns 588,448 shares of the biopharmaceutical company’s stock valued at $17,030,000 after acquiring an additional 51,703 shares during the period. Blueshift Asset Management LLC grew its holdings in shares of Pfizer by 51.1% during the 3rd quarter. Blueshift Asset Management LLC now owns 48,001 shares of the biopharmaceutical company’s stock worth $1,389,000 after purchasing an additional 16,235 shares in the last quarter. Hardy Reed LLC increased its position in shares of Pfizer by 16.5% in the third quarter. Hardy Reed LLC now owns 11,133 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 1,578 shares during the period. Finally, Townsquare Capital LLC lifted its position in Pfizer by 28.9% during the third quarter. Townsquare Capital LLC now owns 742,714 shares of the biopharmaceutical company’s stock worth $21,494,000 after purchasing an additional 166,709 shares during the period. Institutional investors own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $25.76 on Wednesday. The business has a 50-day moving average of $28.05 and a 200-day moving average of $28.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $145.98 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the business earned ($0.17) EPS. The company’s revenue was up 31.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.52%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analysts Set New Price Targets

Several analysts recently issued reports on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Barclays raised their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Finally, Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.